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Abstract 10 
 Bacteria in the genus Staphylococcus are important targets for phage therapy due to their prevalence 11 
as pathogens and increasing antibiotic resistance. Here we review Staphylococcus outer surface features and 12 
specific phage resistance mechanisms that define host range - the set of strains an individual phage can 13 
potentially infect. Phage infection goes through five distinct phases - attachment, uptake, biosynthesis, 14 
assembly and lysis. Adsorption inhibition, encompassing outer surface teichoic acid receptor alteration, 15 
elimination, or occlusion, limits successful phage attachment and entry. Restriction-modification systems (in 16 
particular, type I and IV systems), which target phage DNA inside the cell, serve as the major barriers to 17 
biosynthesis as well as transduction and horizontal gene transfer between clonal complexes and species. 18 
Resistance to late stages of infection occurs through mechanisms such as assembly interference, in which 19 
staphylococcal pathogenicity islands siphon away superinfecting phage proteins to package their own DNA. 20 
While genes responsible for teichoic acid biosynthesis, capsule, and restriction-modification are found in most 21 
Staphylococcus strains, a variety of other host-range determinants (e.g., CRISPRs, abortive infection, and 22 
superinfection immunity) are sporadic. Fitness costs of phage resistance through teichoic acid structure 23 
alteration could make staphylococcal phage therapies promising, but host range prediction is complex because 24 
of the large number of genes involved, many with unknown roles. In addition, little is known about genetic 25 
determinants that contribute to host range expansion in the phages themselves. Future research must identify 26 
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host range determinants, characterize resistance development during infection and treatment, and examine 27 
population-wide genetic background effects on resistance selection. 28 
Keywords: staphylococci, phage resistance, host range, phage therapy, CRISPR 29 
Introduction 30 
 The Staphylococcus genus includes commensals and pathogens of humans and animals. S. aureus 31 
and S. epidermidis, in particular, cause diverse infections in humans and have become increasingly antibiotic 32 
resistant over the past seventy years. Diseases range from food poisoning to skin and soft tissue infections, 33 
pneumonia, osteomyelitis, endocarditis, and septic shock. S. aureus is carried by between 20% (persistently) 34 
and 60% (intermittently) of the human population (1), primarily on the skin and upper respiratory tract. 35 
Methicillin-resistant S. aureus (MRSA) emerged in the mid-1960s (2) and has reduced the options for 36 
treatment with beta-lactam antibiotics. The combination of high carriage rates, diverse pathologies, prevalent 37 
antimicrobial resistance, and lack of a licensed vaccine (3) makes staphylococcal species important targets for 38 
new therapies.  39 
Bacteriophage (phages) are natural killers of Staphylococcus bacteria lysing bacterial cells through 40 
expression of holins, which permeabilize the membrane and release endolysins (4, 5) that degrade the 41 
peptidoglycan of the cell wall (6). Phage therapy is a promising alternative to antibiotics for treating infections 42 
because of the large number of diverse phages with low toxicity to humans and non-target species (7, 8).  43 
Phage therapy has a long history, reaching back before the antibiotic era to shortly after the discovery 44 
of phages themselves by Frederick Twort and Felix d’Herelle in the 1910s (9–11). While overshadowed by the 45 
subsequent discovery of antibiotics and generally abandoned in the West for many years, phage therapy 46 
persisted as a bacterial treatment in eastern Europe and the nations that composed the former Soviet Union 47 
(9, 10). There, phage cocktails were developed for sepsis, osteomyelitis, and burn wounds, among other 48 
staphylococcal diseases, with complete recovery reported in some cases (12). Polish and Soviet studies 49 
showed that phage lysates effectively treated staphylococcal skin and lung infections (13). More recently, the 50 
emergence of multi-drug resistance in bacterial pathogens has renewed interest in phage therapy and phage 51 
biology (8, 14). Safety studies on the staphylococcal phage lysate (SPL) as well as phage cocktails containing 52 
S. aureus-specific phages indicated that they had no adverse effects when administered intranasally, 53 
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intravenously, orally, topically, or subcutaneously (14). Phages have also been recently approved by the FDA 54 
as a treatment to clear another Gram-positive species (Listeria monocytogenes) present in food (15) and 55 
approved as personalized treatment for burn wound infections (16). 56 
All known staphylococcal phages are members of the order Caudovirales with linear dsDNA virion 57 
genomes. Staphylococcal phages are divided into three families with distinctive morphologies – the long, 58 
noncontractile-tailed Siphoviridae, the contractile-tailed Myoviridae, and the short, noncontractile-tailed 59 
Podoviridae (17, 18). Siphoviridae genomes are 39-43 kb in size, while those of the Myoviridae are 120-140 kb 60 
and Podoviridae are 16-18 kb (17). Currently reported Siphoviridae are typically temperate phages that encode 61 
lysogeny functions within a genomic module, while reported Myoviridae and Podoviridae are virulent. The 62 
virulent phages are the strongest potential candidates for phage therapy, given that they are not known to 63 
lysogenize and thus obligately kill their targets. Lytic staphylococcal phages have surprisingly broad host 64 
ranges (19–22), anti-biofilm activity (19, 23), and varying effectiveness against infection (24–26). The 65 
Siphoviridae are agents of horizontal gene transfer (HGT) through transduction (27) into recipient strains (17) 66 
and activation of staphylococcal pathogenicity islands (SaPIs) (28). The Siphoviridae have been subdivided 67 
into “integrase types” based on the sequence of the integrase gene necessary for lysogenic insertion into the 68 
chromosome (17, 29). Certain integrase type phages introduce specific virulence factors (17). Integrase type 3 69 
(Sa3int) phages encode the immune evasion cluster (IEC), which includes the staphylokinase (sak), 70 
staphylococcal complement inhibitor (scn), chemotaxis inhibitory protein (chp), and enterotoxin S (sea). In 71 
addition, Sa2int phage often encode Panton-Valentine leukocidin (lukFS-PV), while Sa1int phages often 72 
encode exfoliative toxin A (eta). Temperate staphylococcal phages can also disrupt chromosomal virulence 73 
factors (17). Sa3int and Sa6int phages, for example, integrate into sites in the beta-hemolysin (hlb) or lipase 74 
(geh) genes, respectively (30, 31). 75 
No single phage can kill every Staphylococcus strain. Instead, each phage has a particular host range, 76 
defined as the set of strains permissive for its infection.  Host range can be limited by active host resistance 77 
mechanisms such as CRISPR or restriction-modification that actively suppress phage infection or by passive 78 
mechanisms such as loss of receptors for phage adsorption. It is unclear whether these host range limiting 79 
factors have arisen through specific adaptation against phage infection or are byproducts of selection against 80 
other stresses. There are, however, specific phage counteracting mechanisms to host resistance that serve to 81 
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broaden phage host range. Phage host range has great importance to phage therapy because it defines the 82 
potential scope of treatable strains, thus informing selection of phages for rational, personalized cocktail 83 
development.  84 
Mechanisms of resistance to phage have been reviewed previously across bacteria generally (32, 33) 85 
and in lactic acid bacteria (34), but this is the first article to focus on the particular features of Staphylococcus 86 
(Figure 1).  By far, the majority of the literature has focused on two species: S. epidermidis, and especially, S. 87 
aureus. However, we include studies on other species (e.g. S. simulans) where appropriate. We then reflect on 88 
possible consequences of resistance on phage host range and potential phage therapy for staphylococcal 89 
infections, given that phage resistance elements determine host range and thus provide one criterion for phage 90 
efficacy in therapy. We also consider the evolutionary trade-offs of phage resistance in a therapeutic context 91 
due to the potential effects of phage resistance on either virulence or antibiotic resistance.  92 
Host resistance can occur at different points in the phage life cycle (Figure 1) (32, 33).  There are no 93 
reports in Staphylococcus of mechanisms that limit host range at the uptake and host lysis phases.  We 94 
therefore concentrate on the attachment, biosynthesis, and assembly phases. 95 
Attachment  96 
Wall teichoic acid is the primary staphylococcal phage receptor 97 
Attachment of phages to the outside of the Staphylococcus cell (Figure 2A) is the first stage of infection 98 
(Figure 1). Staphylococcus may be resistant to phage adsorption if the receptor molecule is not present, not 99 
recognized by the phage, or blocked. Mutations that alter components of the outer surface can have the effect 100 
of inhibiting adsorption and thus conferring resistance. Through genetic and biochemical studies on a small 101 
range of staphylococcal phages, the polyribitol phosphate (poly-RboP) polymer of wall teichoic acid (WTA) or 102 
N-acetylglucosamine (GlcNAc) modifications at the 4 positions of ribitol phosphate monomers in WTA appear 103 
to be the primary targets (35–41). 104 
In an early S. aureus phage resistance study published in 1969, N-methyl-N'-nitro-N-nitrosoguanidine-105 
mutagenized strain H (Multi Locus Sequence Type 30; ST30) (42) phage-resistant mutants were selected by 106 
plating on agar plates containing lawns of 52A (siphovirus) (40). Mutants also found resistant to phage K 107 
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(myovirus) were deficient in N-acetylglucosamine, cell wall phosphorus, and ester-linked D-alanine in their 108 
envelopes, presumably due to a loss of wall teichoic acid production. Further biochemical characterization 109 
showed that the mutants lacked UDP-GlcNAc:polyribitol phosphate transferase activity and WTA. 110 
Counterintuitively, they did show the relevant biochemical activity for the last known step in WTA biosynthesis 111 
(phosphoribitol transferase – TarL, Figure 2B) (38). This surprising result suggested the double resistant 112 
mutants produced ribitol phosphate but either failed to properly polymerize WTA or attach it to the cell wall. 113 
These mutants had pleiotropic phenotypic differences from their parent strain (41), including a longer 114 
generation time than its parent; cell growth in clumps; irregular, rough, gray colonies; and increased levels of 115 
wall-bound autolysin. A later study characterizing spontaneous S. aureus strain A170 (ST45) mutants resistant 116 
to siphovirus MSa found similar phenotypic defects (43) and biochemical assays also showed that resistance 117 
was likely due to the lack of GlcNAc-modified WTA.  118 
 Peschel and colleagues identified genes responsible for phage adsorption in a series of elegant 119 
molecular genetic studies in the RN4220 (ST8) (44) background (35, 36, 45). Deletion of undecaprenyl-120 
phosphate N-acetylglucosaminyl 1-phosphate transferase (tagO), the first gene involved in WTA biosynthesis, 121 
conferred resistance and reduced adsorption to tested Myoviridae (Φ812 and ΦK), while a transposon 122 
insertion mutant in the tarM gene had resistance and reduced adsorption to Siphoviridae (ΦSa2mw, Φ47, Φ13, 123 
and Φ77). Complementation of wild-type alleles rescued these phenotypes (35). TarM is a glycosyltransferase 124 
responsible for attaching α-O-GlcNAc to the 4 position of the ribitol phosphate WTA monomer (46, 47). The 125 
tarM mutant was previously shown to lack GlcNAc-modified WTA in its envelope (46). TarS, the 126 
glycosyltransferase responsible for attaching β-O-GlcNAc to the 4 position of the ribitol phosphate WTA 127 
monomer (48), was specifically required for podovirus adsorption (45). Deletion of tarS conferred resistance 128 
and reduced adsorption to tested Podoviridae (Φ44AHJD, Φ66, and ΦP68) (45), but only deletion of both tarS 129 
and tarM conferred reduced adsorption to tested Siphoviridae (Φ11) in the same RN4220 background used in 130 
prior studies (49, 50). On the other hand, even tarS+, tarM+ strains were resistant to Podoviridae, suggesting 131 
WTA decorated with α-O-GlcNAc by TarM impeded podovirus adsorption (45). Taken together, these findings 132 
suggested, for the small number of representatives that were tested, elimination of WTA confers resistance to 133 
all classes of phage, elimination of GlcNAc modifications confers resistance to the Siphoviridae and 134 
Podoviridae, and elimination of β-O-GlcNAc modification confers resistance specifically to the Podoviridae. 135 
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Given the conservation of wall teichoic acid biosynthesis genes amongst S. aureus genomes (51) and the 136 
cross-species activity of staphylococcal phages such as phage K (52), these conclusions could be expected to 137 
hold in staphylococci beyond S. aureus. 138 
Recent studies have suggested that as the number of strains and phages expands we may find a larger 139 
number of genes influencing host range through attachment. Azam et al. conducted a long-term evolution 140 
experiment in which they selected S. aureus SA003 (ST352) mutants resistant to myovirus ΦSA012 (53). 141 
Resistant mutants gained missense mutations in five genes (tagO, RNase adapter protein rapZ, putative 142 
membrane protein yozB, guanylate kinase gmk, and alpha subunit of DNA-dependent RNA polymerase rpoA), 143 
a nonsense mutation in one gene (UDP-N-acetylglucosamine 1-carboxyvinyltransferase murA2), and a 1,779 144 
bp deletion that included the C-terminal region of the teichoic acid glycosyltransferase tarS, a non-coding 145 
region, and the N-terminal region of the iron-sulfur repair protein scd. Complementation of mutations in genes 146 
scd, tagO, rapZ, and murA2 restored ΦSA012 sensitivity and adsorption, while only complementation of 147 
mutations in tarS restored sensitivity and adsorption of another myovirus, ΦSA039. The results suggested that 148 
while ΦSA012 recognized the WTA backbone, ΦSA039 was unusual in recognizing β-O-GlcNAc-modified 149 
WTA, hinting that there may be more variability in receptor targets within phage groups than the limited number 150 
of earlier studies suggested. 151 
The carriage of a prophage in certain S. aureus CC5 and CC398 strains that encodes alternative WTA 152 
glycosyltransferase tarP (54) adds further complications. TarP attaches GlcNAc to the 3 position of ribitol 153 
phosphate rather than the 4 position, thus conferring Siphoviridae (Φ11, Φ52a, Φ80) sensitivity but 154 
Podoviridae (Φ44, Φ66, and ΦP68) resistance. It is interesting in the light of host range evolution that a gene 155 
carried on a prophage can change the properties of the S. aureus surface and thus affect the host ranges of 156 
other phages.  157 
Although the majority of staphylococcal phage tested bind WTA and GlcNAc receptors, there is one 158 
known exception. Siphovirus Φ187 binds WTA glycosylated with N-acetyl-D-galactosamine (GalNAc), the 159 
unusual WTA synthesized by S. aureus ST395 (55). The α-O-GalNAc transferase tagN, the nucleotide sugar 160 
epimerase tagV, and the short GroP WTA polymerase tagF genes are required specifically for synthesis of 161 
ST395 WTA. Homologs of these genes were found in genomes of multiple Coagulase-Negative Staphylococci 162 
(CoNS) strains, such as S. pseudointermedius ED99, S. epidermidis M23864:W1, and S. lugdunensis 163 
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N920143. Complementation of a S. aureus PS187 tagN C-terminal glycosyltransferase deletion with the wild-164 
type tagN gene or that from S. carnosus (tagN-Sc) successfully restored the wild-type phenotype, suggesting 165 
tagN homologs in other CoNS genomes had similar functions to that in S. aureus PS187 (ST395). 166 
Complementation of the tagN C-terminal deletion with either PS187 or S. carnosus tagN also restored wild-167 
type Φ187 sensitivity. This difference in WTA structure was shown to prohibit transduction between ST395 and 168 
other S. aureus lineages (56). Staphylococcal pathogenicity island (SaPI) particles prepared in a ST1, 5, 8, 22, 169 
25, or 30 strain with phages Φ11 or Φ80α failed to transduce any ST395 strains. SaPI particles prepared in a 170 
ST395 strain, on the other hand, transduced other ST395 strains as well as CoNS species and Listeria 171 
monocytogenes. These findings suggest the unique ST395 WTA restricts phage host range to strains of the 172 
same sequence type or Gram-positives with a related WTA structure, such as Listeria monocytogenes.  173 
There has been one study showing that staphylococcal phages (siphovirus ΦSLT) can bind lipoteichoic 174 
acid (LTA), the lipid-anchored, polyglycerol phosphate (GroP) TA polymer (57) (Figure 2A). However, 175 
subsequent elimination of LTA biosynthesis through ltaS deletion had no effect on phage adsorption or 176 
sensitivity (35) and therefore the potential significance of LTA as an alternative receptor is currently unknown. 177 
The effects of surface proteins and extracellular polysaccharides on attachment 178 
Although proteins serve as receptors for many Gram-positive phages (for example, the YueB receptor 179 
for Bacillus subtilis phage SPP1 (58)), there is no evidence to suggest S. aureus proteins serve as its phage 180 
receptors. Phage interaction protein (Pip) homologs exist throughout the Gram-positives, serving as protein 181 
receptors to which phage irreversibly bind (59). There are Pip surface protein homologs anchored to the 182 
staphylococcal cell wall through the action of the sortase enzyme in Staphylococcus (60, 61). However, neither 183 
deletion of the Pip homologs in RN4220 (ST8) (49) nor sortase A in Newman (ST254) (62, 63) affected 184 
sensitivity to phage Φ11 and phages ΦNM1, ΦNM2, and ΦNM4, respectively. 185 
 Some classes of proteins or extracellular polysaccharides have been shown to block phage adsorption 186 
in the staphylococci through occlusion of the WTA receptors. Overproduction of surface protein A in S. aureus 187 
was shown to reduce phage adsorption through this mechanism (64), but work on surface protein occlusion 188 
remains limited. Capsule types 1 and 2 - strains M (ST1254) (42) and Smith diffuse (ST707) (42), respectively - 189 
were shown to occlude adsorption (65), but the most common capsule types, 5 and 8, showed inconclusive 190 
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results (66, 67). Differences in capsule thickness between strains may account for these variable results. Type 191 
1 and 2 strains are mucoid and heavily encapsulated, while type 5 and 8 are non-mucoid despite 192 
encapsulation (68). The CoNS species Staphylococcus simulans also showed capsule-dependent inhibition of 193 
phage adsorption (69).  194 
The exopolysaccharides (EPS) of staphylococcal biofilms have not been shown to occlude adsorption.  195 
Surface proteins, such as biofilm-associated protein (Bap), exopolysaccharides (polysaccharide intercellular 196 
adhesin - PIA - composed of poly-N-acetylglucosamine – PNAG – and synthesized by the products of the 197 
icaADBC operon), and extracellular DNA (eDNA) compose staphylococcal biofilms, which can form by PIA-198 
dependent or protein (Bap)-dependent mechanisms (70, 71). Other surface proteins more common than Bap 199 
can also mediate biofilm formation, such as FnbA/FnbB (72, 73) and SasG (74) in S. aureus and Aap in S. 200 
epidermidis (70). Both S. aureus (19, 75) and S. epidermidis (52, 76, 77) biofilms are susceptible to phage 201 
predation. Phage resistance in staphylococcal biofilms may instead be associated with altered biofilm diffusion 202 
or metabolism, the latter of which resembles stationary phase growth. Studies on S. epidermidis suggested 203 
phage susceptibility was similar in biofilms and stationary phase cultures (52). Phages may in fact promote 204 
bacterial persistence in S. aureus biofilms by releasing nutrients from lysed cells for remaining live ones to 205 
utilize (78). 206 
Biosynthesis 207 
Superinfection immunity 208 
Staphylococcal temperate phages encode homologs of the cI repressor (17, 18). In E. coli, this protein 209 
represses expression of the lytic cycle in newly infecting phages with the same cI protein-binding sites, thus 210 
stopping new infections through a mechanism called superinfection immunity. Molecular and evolutionary 211 
studies on the E. coli phage lambda model suggest many superinfection immunity groups (in which member 212 
temperate phages confer immunity to each other upon integration) coexist in nature (79), with cI repressor – 213 
operator coevolution driving the emergence of new immunity groups (80). Superinfection immunity as a 214 
determining factor in phage host range in staphylococcal species appears not to have been studied yet, but 215 
since prophages are common (most sequenced S. aureus genomes contain 1-4 prophages) (18, 81), it may be 216 
a significant barrier to phage infection. 217 
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Restriction-modification (R-M) systems 218 
 Bacteria can resist phage infection by degrading injected phage DNA before it has the chance to 219 
replicate and enter the lytic or lysogenic cycle (Figure 1). Restriction-modification (R-M) is a prominent phage 220 
infection barrier in the Staphylococcus genus. R-M systems are modular operons containing combinations of 221 
host specificity determinant (hsd) genes encoding three types of functions: restriction endonuclease activity 222 
(hsdR) responsible for destroying unmodified DNA, DNA adenosine or cytosine methyltransferase activity 223 
(hsdM) responsible for modifying host DNA so that it is not cleaved by restriction endonucleases, and 224 
specificity DNA-binding proteins (hsdS) responsible for recognizing sequence motifs targeted for cleavage or 225 
modification (82).  226 
There are four known types of R-M systems in bacteria, all of which have been found in the 227 
staphylococci (83). In type I systems, the restriction enzyme cleaves unmodified DNA adjacent to its binding 228 
site, sometimes separated by as much as 1000 bp from the binding site, while the modification enzyme 229 
methylates host DNA at the target site specified by the specificity protein. A complex containing all three types 230 
of subunits restricts unmodified exogenous DNA, while HsdSHsdM complexes only modify DNA. In type II 231 
systems, the restriction enzyme (HsdR2) cleaves unmodified DNA at its binding site, while the modification 232 
enzyme (HsdM) modifies DNA at this site. In type III systems, the restriction enzyme cleaves unmodified DNA 233 
roughly 24-28 bp downstream from its asymmetric target site, while the modification enzyme methylates a 234 
single strand of host DNA at the target site. The modification subunit (Mod) modifies one strand of DNA either 235 
by itself (Mod2) or in complex with the restriction subunit (e.g., Mod2Res1 or Mod2Res2), while the restriction 236 
subunit (Res) cleaves unmodified DNA only in complex with modification subunits (Mod2Res1 or Mod2Res2). In 237 
type IV systems, the restriction enzyme only cleaves modified, methylated DNA. Type IV systems do not 238 
include a modification enzyme. These systems have been well studied in S. aureus (and in S. epidermidis, to a 239 
more limited extent) due to their role in restricting natural horizontal gene transfer and genetic manipulation of 240 
the organism (83–86).  241 
Type I R-M systems are the most abundant class of R-M systems reported in S. aureus, followed by 242 
type IV and then type II systems (83). Type III systems appear to be rare, with only two described in the genus 243 
(83).  Analyses of the restriction enzyme genomic database REBASE in 2014 showed that all completed S. 244 
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aureus genomes encode a type I R-M system and that most S. aureus genomes annotated with R-M genes 245 
encode a type I system (83, 87). The most common type I R-M locus found in S. aureus is Sau1 (88). 246 
Expressing a functional Sau1 hsdR gene in restriction-deficient S. aureus strain RN4220 greatly reduced 247 
electroporation, conjugation, and transduction frequencies (88). S. aureus genomes generally encode two 248 
Sau1 hsdS genes that specify two distinct DNA motif targets for restriction or modification (89). The Sau1 249 
HsdS subunit determines target specificity through its two target recognition domains (TRDs), which each bind 250 
to one part of the target sequence (90). TRDs are the least conserved portions of the HsdS amino acid 251 
sequences (88), and vary in carriage between strains with lineage and/or clonal complex-specific variant 252 
associations, as microarray hybridization studies indicate (88, 89). The Sau1 system prevented transfer of 253 
plasmid DNA from one clonal complex (CC5) to another (CC8) with a different target recognition site (89), 254 
showing that restriction defines barriers between clonal complexes. Sau1 also affected susceptibility of two 255 
CC8 strains (NCTC8325-4 and RN4220 phsdR) but not the hsdR-deficient RN4220 to phage Φ75 (siphovirus) 256 
propagated in a CC51 strain (879R4RF), suggesting Sau1 can control phage host range (88). Sau1 variation is 257 
a powerful marker of lineage/clonal complex (88, 91) and likely drives the independent evolution of clonal 258 
complexes. Sau1 would therefore be predicted to be a major host range limitation to phages grown in a strain 259 
of a different clonal complex. Since the target sites of nearly all S. aureus Sau1 R-Ms from each of the different 260 
clonal complexes have now been identified (90), it should be possible to bioinformatically predict the Sau1-261 
defined clonal complex host range of any sequenced bacteriophage. 262 
Type IV R-M system SauUSI is estimated to be found in 90% of S. aureus strains (83, 92) and, in 263 
combination with Sau1, presents an effective restriction barrier for resisting phage infection (93). SauUSI 264 
specifically restricts DNA methylated or hydroxymethylated at the C5 position of cytosine (92). The preferred 265 
binding site for SauUSI is Sm5CNGS, where S represents either cytosine or guanine (92).  Type II R-M 266 
systems have been estimated to be in ~33% of  strains and display a range of target sites (83, 94–96). The 267 
most common type II R-M system found in S. aureus is called Sau3A (94). The Sau3A restriction enzyme 268 
cleaves 5’ to the guanine in unmodified 5’-GATC-3’ sequences. The Sau3A modification enzyme, on the other 269 
hand, methylates the restriction site at the C5 position of cytosine (97). Some type II systems, such as Sau42I, 270 
are encoded by phages. Sau42I is an example of a type IIS R-M system, which binds asymmetric DNA 271 
sequences and cleaves outside the recognition site, unlike most type II systems (82). Unlike type I and type IV, 272 
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type II systems are often carried on mobile genetic elements which are capable of frequent transfer between 273 
strains and are not conserved amongst all members of the same clonal complex, so they present a more 274 
strain-specific and variable limit to host range (87). Certain S. aureus type II R-M systems (e.g., Sau96I) serve 275 
to negate the Type IV SauUSI system because they methylate cytosines and guanines in sequences SauUSI 276 
targets for cleavage. This is an interesting example of how R-M systems acquired by HGT can have 277 
unpredictable interactions with existing systems. 278 
If unmodified phages can survive restriction enzyme degradation upon cell entry, the phage DNA 279 
molecules acquire protective DNA methylation as they replicate. While survival of restriction can happen 280 
stochastically at high multiplicities of infection, phages have also been shown to have evolved or acquired 281 
adaptations for restriction evasion. Anti-restriction mechanisms include restriction site alteration, restriction site 282 
occlusion, indirect subversion of restriction-modification activity, and direct inhibition of restriction-modification 283 
systems (98). Restriction site alteration can include both incorporation of alternative bases, such as 5-284 
hydroxymethyluracil (5hmU) and 5-hydroxymethylcytosine (5hmC), and loss of restriction sites through 285 
selection.  A clear example of the latter in the staphylococci is the elimination of GATC sites in the 140 kb 286 
phage K genome, enabling its avoidance of Sau3A restriction (99). Another example is the evolution of 287 
particular antimicrobial resistance-carrying conjugative plasmids which have lost specific Sau1 R-M sites 288 
allowing their transfer between common MRSA lineages (88). Restriction site occlusion refers to DNA-binding 289 
proteins preventing restriction enzymes from binding and digesting DNA (98, 100, 101). R-M subversion either 290 
occurs through stimulation of host modification enzymes or destruction of restriction cofactors (e.g., SAM) (98, 291 
102, 103). R-M inhibition occurs most often in type I systems (but also in some type II systems) through the 292 
binding of specific anti-restriction proteins, such as ArdA, ArdB, and Ocr (98, 104, 105). There is no literature 293 
specifically characterizing anti-restriction in Staphylococcus, but an E. coli ardA homolog has been identified in 294 
the staphylococcal Tn916 and Tn5801 transposons (106). 295 
Clustered regularly interspaced short palindromic repeat (CRISPR) systems 296 
CRISPRs confer immunity to phage infection through the cleavage of extrinsic DNA in a sequence-297 
specific manner. Unlike R-M systems, which target specific DNA sequence motifs, CRISPRs adaptively 298 
incorporate target sequences from phages they have destroyed to increase the efficiency of protection. After 299 
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integrating short segments of foreign DNA as spacers of CRISPR arrays, CRISPR-associated (Cas) nucleases 300 
process the transcribed CRISPR array RNA into CRISPR RNAs (crRNAs) used to target new incursions of 301 
identical foreign DNA elements for destruction (107, 108). Surveys of S. aureus and S. epidermidis genomes 302 
indicate CRISPRs are not common in these species (109, 110). These surveys looked for the presence of cas6 303 
and cas9 genes, which are nucleases required for Type I/III and Type II CRISPR-mediated resistance, 304 
respectively. Cas6 is an endoribonuclease found in Type I and III CRISPR systems that cleaves pre-crRNA 305 
transcripts within the 3’ end of the repeat region to produce mature guide crRNAs (111, 112), while Cas9 is an 306 
endonuclease found in Type II CRISPR systems that cleaves DNA in a crRNA-guided manner (112, 113). Only 307 
12 of 300 published S. epidermidis genomes searched encoded the Cas6 nuclease, 18 of 130 S. epidermidis 308 
isolates from Denmark (Copenhagen University Hospital) tested positive for cas6 via PCR, and 14 of nearly 309 
5000 published S. aureus genomes encoded CRISPR/Cas systems (109). Another study specifically 310 
examining S. aureus found that 2 of 32 S. aureus strains encoded CRISPR/Cas systems (110). These 311 
CRISPRs were similar to those found in two S. lugdunensis strains, suggesting they were recombined with S. 312 
lugdunensis or derived from a common ancestor (110). CRISPR/Cas systems have also occasionally been 313 
reported in strains of other species (S. capitis, S. schleifer, S. intermedius, S. argenteus, and S. microti) (109). 314 
Only a single S. aureus strain has been reported to encode Cas9, which is found in an SCCmec-like region 315 
(114). Nonetheless, CRISPR systems have been shown to be important in resisting introduction of foreign 316 
DNA in S. epidermidis RP62a (115, 116). Anti-CRISPR mechanisms, such as proteins that prevent CRISPR-317 
Cas systems from binding DNA target sites, are being discovered in many phages (117–119), although not yet 318 
in those specific for staphylococci. Currently discovered anti-CRISPR mechanisms have been shown to target 319 
both type I and type II CRISPR systems (117–120). 320 
Assembly 321 
 Assembly interference is the parasitization of superinfecting phage by chromosomal phage-like 322 
elements and has been demonstrated experimentally in S. aureus pathogenicity island (SaPI)-helper phage 323 
interactions. SaPIs encode important virulence factors, such as toxic shock syndrome toxin (TSST), but are 324 
only mobilized by superinfecting helper siphoviruses (28, 121). The Dut dUTPase protein expressed by helper 325 
phages derepresses the Stl SaPI repressor, activating the SaPI lytic cycle (28). The derepressed SaPIs then 326 
take advantage of the superinfection to proliferate at the expense of the helper phage. SaPIs interfere with 327 
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helper phage assembly through several mechanisms (122) - remodeling phage capsid proteins to fit the small 328 
SaPI genome (123–127), encoding phage packaging interference (Ppi) proteins that prevent helper phage 329 
DNA packaging into new SaPI particles (123), and disrupting phage late gene activation (128). All known 330 
SaPIs encode phage packaging interference (Ppi) proteins, which divert phage DNA packaging toward SaPIs 331 
by inhibiting helper phage terminase small subunits (TerSP) but not corresponding SaPI subunits (TerSS) (123). 332 
Ppi proteins are divided into two classes based on sequence that differ in helper phage specificity – Class I 333 
interferes with Φ80α and Φ11, while Class II interferes with Φ12 (123). The PtiM-modulated PtiA and the PtiB 334 
SaPI2 proteins inhibit expression of the LtrC-activated phage 80 late gene operon (packaging and lysis genes), 335 
thus interfering with later steps of the helper phage life cycle (128). The SaPI particles then go on to infect new 336 
S. aureus hosts, integrating their DNA into the chromosome instead of killing the cell. Helper phages and 337 
SaPIs are thought to gain and lose resistance to each other in a ‘Red Queen’ scenario, given the observed 338 
rapid co-evolution of their respective dut and stl genes (129). SaPIs are found throughout Staphylococcus 339 
species and beyond; therefore, they may be a common strain-specific modifier of siphovirus infection potential. 340 
Other phage host range limiting factors 341 
 Several uncommon or less well-understood mechanisms may contribute to phage host range limitation 342 
in Staphylococcus. One abortive infection (Abi) system, the eukaryotic-like serine/threonine kinase Stk2, has 343 
been characterized in S. aureus and S. epidermidis (130). In this case, siphovirus infection results in self-344 
induced killing of the host cell, preventing the amplification and spread of phages in the population. Stk2 was 345 
found to be activated by a phage protein of unknown function and caused cell death by phosphorylating host 346 
proteins involved in diverse core cellular functions. Only S. epidermidis RP62A and a few S. aureus strains 347 
encode Stk2, however, suggesting limited genus-wide importance. The recent long-term evolution study on S. 348 
aureus strain SA003 uncovered two genes involved in post-adsorption resistance to myovirus ΦSA012 (53). 349 
Missense mutations in guanylate kinase and the alpha subunit of DNA-dependent RNA polymerase conferred 350 
resistance but not corresponding decreases in adsorption rate, suggesting some post-adsorption role in 351 
resisting infection. More phage resistance systems likely remain undiscovered. A genome-wide association 352 
study of 207 clinical MRSA strains and 12 phage preparations identified 167 gene families putatively 353 
associated with phage-bacterial interactions (131). While these families included restriction-modification genes, 354 
 o
n
 M
ay 3, 2019 by guest
http://aem
.asm
.org/
D
ow
nloaded from
 
transcriptional regulators, and genes of prophage and SaPI origin, most were accessory gene families of 355 
unknown function.   356 
Phage host range in Staphylococcus is determined by a hierarchical 357 
combination of host factors 358 
In summary, we have described how host range of a Staphylococcus phage is determined by a 359 
combination of both host and phage-encoded genes, as well as the epigenetic DNA methylation patterns 360 
conferred on its DNA from the last strain it infected. Bacterial encoded factors can be conceived as affecting 361 
host range at different levels within the species (Figure 3). At the highest level, most phages’ target for 362 
receptor binding (WTA) is highly conserved across Staphylococcus species. Strains with unusual WTAs, such 363 
as S. aureus ST395 and CoNS strains with poly-GroP WTA (55, 56), would be expected to be genetically 364 
isolated within the genus. Type I and IV R-M HsdS allotypes and capsule type are conserved between most 365 
strains of the same CC but differ between isolates of different CC groups and thus contribute to defining host 366 
range in a large subset of S. aureus strains. At the level of individual strains, inserted prophages and SaPIs, 367 
Stk2, type II systems acquired by HGT, and other as yet unknown functions may all serve to limit host range. 368 
We know even less about phage-encoded systems that counteract host resistance. The finding that lytic 369 
phages (Myoviridae and Podoviridae) tend to have broader host ranges than Siphoviridae when challenged 370 
against the same set of Staphylococcus strains suggests the former encode an array of uncharacterized genes 371 
that work against host defenses. 372 
Future directions 373 
 Although much progress has been made in the past five decades toward understanding the 374 
mechanisms that define staphylococcal phage host range, numerous important questions remain. We need to 375 
know more about species other than S. aureus and S. epidermidis, and even within these species, we need to 376 
make sure that rarer and non-methicillin resistant strains are included in studies (132). We also need to ensure 377 
that our collections reflect the true diversity of phages that infect Staphylococcus species. Even within the two 378 
main species only a relatively small number of phages have been tested. This will lead us to consider the 379 
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questions of phage ecology when understanding what types of phages are found in different environments and 380 
with what abundance. 381 
 Discovering novel phage resistance mechanisms would aid the effort to understand determinants of 382 
host range. Many phage resistance mechanisms have been identified and characterized in other Gram-383 
positives and other bacteria generally but not in the staphylococci. Superinfection exclusion (Sie) and abortive 384 
infection (Abi) systems, for example, are well-characterized in the lactococci (133–135). In addition, a recent 385 
publication describes some 26 new anti-phage defense systems identified in bacteria (136), not including the 386 
recently discovered bacteriophage exclusion (BREX) and defense island system associated with restriction-387 
modification (DISARM) phage defenses (137–139). Six of the ten verified, newly discovered anti-phage 388 
defense systems (Thoeris, Hachiman, Gabija, Septu, Lamassu, and Kiwa) have orthologs in staphylococcal 389 
genomes (136).  390 
Understanding phage host range to the point that we can make accurate predictions based on the host 391 
genome will be important for developing phage therapies against Staphylococcus strains. Ideally, cocktail 392 
formulations for therapy consist of phages with broad, non-overlapping host ranges against the target species 393 
(or clonal complex) to be treated. As there are many more genome sequences available than strains that can 394 
be tested for sensitivity in the laboratory (e.g > 40,000 for S. aureus) (140), with a predictive model we could 395 
run in silico tests on genome sequences to model the efficacy of the cocktail. With the potential for genome 396 
sequencing to be used in the future as a primary clinical diagnostic, we could modify the cocktail to contain 397 
phages that specifically target the bacterium causing the infection. 398 
Knowledge of phage host range will also lead us to understand the fitness costs of resistance and its 399 
potential trade-offs with virulence and antibiotic resistance of Staphylococcus. Strains with null mutations in 400 
biosynthetic genes are rare, given WTA’s roles in cell division, autolysis, virulence, and antibiotic resistance 401 
(36, 37). Although knocking out the genes involved in the first two steps of WTA biosynthesis has no fitness 402 
cost in S. aureus (at least in laboratory conditions) (141, 142), WTA has many critical physiological roles, 403 
especially in environments subject to phage therapy. Staphylococcal WTA is required for nasal colonization 404 
(141, 143), cell division (41, 43), regulating autolysis (144, 145), lysozyme resistance through cell wall 405 
crosslinking (132, 146), resistance to cationic antimicrobial peptides and fatty acids (147, 148), and biofilm 406 
formation (149). WTA-altered or negative phage-resistant mutants would in turn become less virulent (43) and 407 
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even antibiotic sensitive – highly unfit in the natural habitat colonizing mammalian hosts or in an infection site 408 
subject to treatment. Given that methicillin resistance requires WTA (50), phage/beta-lactam combination 409 
therapies could be particularly promising. Mutants resistant to either phage or beta-lactams would be sensitive 410 
to the other treatment, assuming the infecting strain is sensitive to the phage treatment. Nonetheless, as we 411 
note for host range, strains containing minor but fitness-neutral resistance mechanisms, such as R-M systems 412 
– rather than costly mutations – may be the most recalcitrant to phage therapy. Staphylococcal phage 413 
therapies must then overcome both immediate, emerging mutational resistance and intrinsic resistance 414 
mechanisms (e.g., R-M systems) specific to strains or clonal complexes. These resistance limitations, 415 
however, could be overcome by selecting phage host range mutants that escaped host resistance 416 
mechanisms, thus isolating more useful phages that would form more effective phage cocktails (150, 151). 417 
Phage-resistant mutants isolated so far, such as those described in the adsorption studies, were 418 
typically selected in rich, aerated laboratory medium. The consequences for fitness of the same mutations 419 
occurring during in vivo infection might be more severe. In addition, both the relevance of various resistance 420 
mechanisms in vivo and the effect of strain genetic background on resistance selection - especially on a 421 
species-wide scale – have been left unexamined in most previous work. One study in mammalian hosts 422 
showed that environment altered phage transfer frequency and selection (152), leading to spread of prophage 423 
and selection of phage resistance by superimmunity. In laboratory media, phage transfer frequency was lower 424 
and spread of prophage was less pronounced (152). It will be important to know both how quickly and in which 425 
loci mutations emerge as well as the more general distribution of resistance gene families.  426 
Finally, it is interesting to consider what phage host range studies reveal about the hosts themselves.  427 
Staphylococci seem to be unusual among Gram-positives in requiring conserved WTA receptors for 428 
attachment and having no reported role for protein receptors. Differences in the outer surface of 429 
Staphylococcus and/or a feature of the phage ecology within the genus requiring highly conserved receptors 430 
may account for this fact. Another interesting question is why CRISPRs play a much-reduced role for 431 
intercepting extrinsic phage DNA than R-M systems in this genus compared to other bacteria. It could be that 432 
CRISPR systems have a finite capacity for carrying fragments of mobile genetic elements, while R-M systems 433 
can attack a wider range of incoming DNA, relevant to rapidly evolving populations. Future studies that probe 434 
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these questions may reveal some of the differential evolutionary forces that shape the genomes of pathogenic 435 
bacteria. 436 
Conclusions 437 
Staphylococcal phage resistance mechanisms have been identified at three stages of infection 438 
(attachment, biosynthesis, and assembly) and regulate host range in a hierarchical manner depending on 439 
mechanism conservation. Nonetheless, staphylococcal phage-bacterial interactions certainly present many 440 
open questions that must be addressed to accurately develop and evaluate possible phage therapies. We 441 
need further studies to objectively identify the contribution of individual phage resistance mechanisms to host 442 
range. Such work would provide the information needed not only to formulate phage cocktails effective against 443 
a wide variety of strains but also to overcome remaining obstacles to cocktail development (e.g., highly 444 
effective R-M or Abi systems). Future studies relevant to phage therapy should also characterize phage 445 
resistance development during infection and therapy as well as the effects of resistance on mutant fitness. 446 
Taken together, this future work will inform the rational design of phage cocktails to treat staphylococcal 447 
infections alone or in combination with antibiotics. 448 
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 839 
 840 
Figures 841 
Figure 1: Stages of phage infection and corresponding examples of resistance mechanisms at each stage. 842 
Examples not yet identified in the staphylococci are listed in red. 843 
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 845 
 846 
 847 
 848 
 849 
 850 
Figure 2: A - The structure of the staphylococcal cell envelope. Lipoteichoic acid is shown in orange (glycerol 851 
phosphate), a surface protein in black, wall teichoic acid in orange (glycerol phosphate) and yellow (ribitol 852 
phosphate), capsule in blue, and cell wall carbohydrates in green (N-acetylglucosamine – GlcNAc) and purple 853 
(N-acetylmuramic acid – MurNAc). Staphylococcal phages bind WTA and/or its ribitol phosphate modifications 854 
 o
n
 M
ay 3, 2019 by guest
http://aem
.asm
.org/
D
ow
nloaded from
 
(i.e., GlcNAc). B – Outline of the wall teichoic acid (WTA) biosynthesis pathway with proteins corresponding to 855 
each step listed in the blue arrows. Abbreviations are defined as follows - C55-P, undecaprenyl phosphate; 856 
GlcNAc, N-acetylglucosamine; UDP-GlcNAc, uridine-5-diphosphate-N-acetylglucosamine; ManNAc, N-857 
acetylmannosamine; UDP-ManNAc, uridine-5-diphosphate-N-acetylmannosamine; Gro-P, glycerol phosphate; 858 
CDP-Gro, cytidyl diphosphate-glycerol; Rbo-P, ribitol phosphate; CDP-Rbo, cytidyl diphosphate-ribitol; ABC, 859 
ATP-binding cassette; and LCP, LytR-CpsA-Psr.  860 
 861 
 862 
 863 
 864 
Figure 3: Phage host range for an individual strain is the combination of multiple factors that have different 865 
levels of conservation within the species. This is illustrated by a hypothetical phylogenetic tree. Mechanisms 866 
can be present throughout strains (1, most conserved – red), present in many strains but with considerable 867 
allelic variation (2, conserved but polymorphic – shades of green), or present in a few strains, possibly with 868 
allelic variation (3a-3c, less conserved with potential polymorphism – blue, purple, and yellow). Branches 869 
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where mechanisms evolved by mutation or homologous recombination in the case of 1 and 2 or were acquired 870 
by HGT, in the case of 3a-3c, are annotated with colored stars. The table on the right summarizes the 871 
mechanisms (1-3c) present in each strain (A-J) using shaded boxes with corresponding colors. Strain J has a 872 
mutation that results in the null phenotype for the red mechanism. Host range is the result of the combination 873 
of mechanisms present, so strains A-C as well as F, H, and I would be predicted to have identical host ranges, 874 
but phage-specific factors could also introduce variability. 875 
 876 
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